Document:

Exhibit 10.18

 

AMENDMENT

TO

PHARMACY DISTRIBUTION AND SERVICES AGREEMENT

 

THIS AMENDMENT TO PHARMACY DISTRIBUTION AND SERVICES AGREEMENT (“Amendment”) is made effective June 1, 2016 (“Effective Date”) between: CELGENE CORPORATION, 86 Morris Avenue, Summit NJ 07901 (together with its subsidiaries and affiliates, hereinafter collectively “Celgene”) and Diplomat Pharmacy Inc dba Diplomat Specialty Pharmacy,  4100 South Saginaw Street, Flint, MI  48507 (hereinafter, “Pharmacy”).

 

WHEREAS, Celgene and Pharmacy are all of the parties to that certain Pharmacy Distribution and Services Agreement dated July 1, 2013 (the “PDSA”) and wish to amend the PDSA.

 

NOW, THEREFORE, in consideration of the mutual promises contained in this Amendment and other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the parties hereby agree as follows:

 

1.                                      AMENDMENT.  The first sentence of Section 12.1 of the PDSA which reads “This Agreement shall become effective on the Effective Date and, unless earlier terminated in accordance with this Section 12, shall continue in effect for an initial term ending on June 30, 2016.” is hereby deleted and replaced with:

 

This Agreement shall be effective on the Effective Date and, unless terminated in accordance with Section 12, shall continue for a term ending on June 30, 2017.

 

2.                                      NO OTHER CHANGES.  Except as amended by Section 1 above, there are no other amendments to PDSA at this time, and the PDSA as previously amended remains is in full force and effect, valid in accordance with its terms.

 

IN WITNESS WHEREOF, the parties hereby execute and enter into this Amendment as of the Effective Date first written above.

 

THIS AMENDMENT MUST BE EXECUTED, RETURNED TO, AND RECEIVED BY, CELGENE BY 12:00 NOON EST, MONDAY, NOVEMBER 30, 2015 OTHERWISE CELGENE RESERVES THE RIGHT TO RE-EVALUATE THE TERMS OF THIS AMENDMENT, INCLUDING BUT NOT LIMITED TO DECLARING THIS AMENDMENT NULL AND VOID.

 

	
CELGENE   CORPORATION
    	
DIPLOMAT   PHARMACY INC
    
	
 
    	
DBA   DIPLOMAT SPECIALTY PHARMACY
    
	
 
    	
 
    
	
By:
    	
/s/   JAMES KILGALLON
    	
 
    	
By:
    	
/s/   RYAN RUZZICONI
    
	
Name:
    	
James   Kilgallon
    	
 
    	
Name:
    	
Ryan   Ruzziconi
    
	
Title:
    	
Sr.   Director, Pricing & Contracting
    	
 
    	
Title:
    	
VP & General Counsel
    
	
Date:
    	
10/19/2015
    	
 
    	
Date:
    	
9/29/15Exhibit 10.19

 

October 29, 2015

 

Diplomat Pharmacy, Inc., 
 as Borrower, and the other 
 Credit Parties

4100 S. Saginaw Street 
 Flint, Michigan 18507 
 Attention: Sean Whelan, 
 Chief Financial Officer 
 Facsimile: (810) 282-0195

 

Re:                             Diplomat Pharmacy, Inc.

 

Ladies and Gentlemen:

 

Reference is made to the Second Amended and Restated Credit Agreement dated as of April 1, 2015 (as amended, the “Credit Agreement”), by and among Diplomat Pharmacy, Inc., a Michigan corporation (“Borrower”), the other Credit Parties party thereto, and Healthcare Financial Solutions, LLC (successor to General Electric Capital Corporation), in its capacity as agent (in such capacity, “Agent”) for the several financial institutions from time to time party thereto. Capitalized terms used in this letter and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement.

 

Pursuant to Section 4.11(c) of the Credit Agreement, Borrower’s wholly-owned Subsidiary, BioRx, LLC, a Delaware limited liability company (“BioRx”), which is a Credit Party, shall not make any disbursements out of the existing deposit accounts of BioRx at Bank of Kentucky, PNC Bank and Amalgamated Bank (the “Legacy BioRx Accounts”) after October 31, 2015 (other than payment checks and wire transfers payable from such accounts and outstanding against such accounts as of such date and, for the avoidance of doubt, transfers to the deposit accounts at Comerica Bank or another Lender subject to a Control Agreement). Borrower and BioRx have advised Agent that BioRx is unable to have full disbursement capabilities from its new deposit account at Comerica Bank by October 31, 2015, and have requested an extension of the date after which BioRx shall not make any disbursements out of such Legacy BioRx Accounts to January 15, 2016 (the “Extension Request”).

 

Agent has discussed the Extension Request with the Lenders and has received the consent of the Required Lenders to grant the Extension Request. The provisions of Section 4.11(c) of the Credit Agreement as modified hereby continue to apply in all respects, including that in the event that such Legacy BioRx Accounts contain, in the aggregate, $5,000,000 or more at any one time (or, after September 30, 2016, $1,000,000 or more at any one time in accounts not subject to a Control Agreement), then BioRx shall transfer such excess amount to the deposit account(s) at Comerica Bank or another Lender subject to a Control Agreement within three (3) Business Days thereafter.

 

Except to the extent specifically set forth herein, this letter shall not constitute an amendment or waiver by Agent or any Lender of any provisions of the Credit Agreement or any other Loan Document, and all of the provisions of the Credit Agreement and the other Loan

 

 

Documents shall remain in full force and effect to the extent in effect prior to the date hereof. This letter may be executed in any number of several counterparts, each of which shall be an original, but all of which shall constitute one and the same letter agreement. Delivery of an executed counterpart of a signature page to this letter by facsimile transmission shall be effective as delivery of a manually executed counterpart thereof. This letter shall be governed by, and construed and enforced in accordance with, the laws of the State of New York applicable to contracts made and performed in such state, without regard to the principles thereof regarding conflict of laws.

 

[signature pages follow]

 

2

 

	
AGENT:
    	
HEALTHCARE FINANCIAL
    
	
 
    	
SOLUTIONS, LLC, as Agent
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Karen Dahlquist
    
	
 
    	
Name: 
    	
Karen Dahlquist
    
	
 
    	
 
    	
Duly Authorized   Signatory
    

 

3

 

ACKNOWLEDGED AND
 AGREED:

 

	
 
    	
DIPLOMAT PHARMACY, INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Philip Hagerman
    
	
 
    	
 
    	
Name: Philip   Hagerman
    
	
 
    	
 
    	
Title:   CEO
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BIORX, LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Gary Kadlec
    
	
 
    	
 
    	
Name: Gary Kadlec
    
	
 
    	
 
    	
Title:   Manager
    

 

4Exhibit 10.20

 

JOINDER AGREEMENT

 

This Joinder Agreement (“Joinder Agreement”) is entered into as of the 1st day of November, 2015 (the “Joinder Agreement”), by and between AmerisourceBergen Drug Corporation (“ABDC”) “) on the one hand, and Diplomat Pharmacy, Inc., a Michigan corporation (“Diplomat”) for itself and on behalf of the following limited liability companies of which Diplomat is the sole member: Diplomat Specialty Pharmacy of Flint, LLC, Navigator Health Services, LLC, Diplomat Health Services, LLC, Diplomat Specialty Pharmacy of Chicago, LLC, Diplomat Specialty Pharmacy of Ft. Lauderdale, LLC, Diplomat Specialty Pharmacy Great Lakes Distribution Center, LLC, Diplomat Specialty Pharmacy of Southern California, LLC, and Navigator Pharmacy Service, LLC, Burman’s Apothecary, L.L.C. and Burman’s Media Pharmacy, LLC (Diplomat and such limited liability companies being referred to herein collectively as “Customer”) and BioRx, LLC, an Ohio limited liability company (“BioRx”) on the other hand. This Joinder amends the Prime Vendor Agreement between ABDC and Customer effective January 1, 2012, as previcusly amended on July 20, 2012 and further amended on August 1, 2015 (“PVA”). The PVA and this Joinder Agreement shall be collectively referred to as the “Agreement”. Capitalized terms that are not defined in this Joinder Agreement shall have the meanings ascribed to such terms in the PVA.

 

The parties wish to amend the PVA as follows:

 

1.     Joinder of BioRx. The parties recognize that in April 2015, Customer acquired BioRx and BioRx desires to receive pharmaceutical Products and Services from ABDC under the terms and conditions of this PVA. BioRx agrees that the term “Customer” in the PVA shall refer to BioRx. BioRx agrees that by executing this Joinder, it hereby (i) adopts the PVA and agrees to assume and be bound by all the terms, conditions, covenants, responsibilities and provisions thereof and (ii) and all related instruments, agreements and documents; (ii) execute and/or deliver such instruments, agreements and documents as ABDC may reasonably require to effectuate the intents and objects of this provision.

 

2.     This Joinder Agreement constitutes the sole and complete understanding of the parties with respect to its subject matter and supersedes all prior or contemporaneous communications between the parties concerning such subject matter. If there is any conflict between the terms of this Joinder Agreement and the PVA, this Joinder Agreement shall control. Following the Joinder Agreement Effective Date, the Agreement (as amended) remains in full force and effect. This Joinder Agreement shall be governed and construed according to the choice of governing law set forth in the PVA.

 

 

IN WITNESS WHEREOF, the parties have duly executed this Joinder Agreement as of the day and year first above written.

 

AmerisourceBergen Drug Corporation

 

	
By:
    	
/s/ Barry Sandler
    	
 
    
	
Name:
    	
Barry Sandler
    	
 
    
	
Title:
    	
V.P. Strategic Accounts
    	
 
    

 

Diplomat Pharmacy, Inc., for itself and on behalf of the following other entities of which Diplomat Pharmacy, Inc. is the sole member:

 

Diplomat Specialty Pharmacy of Flint, LLC

Navigator Health Services, LLC

Diplomat Health Services, LLC

Diplomat Specialty Pharmacy of Chicago, LLC

Diplomat Specialty Pharmacy of Ft. Lauderdale, LLC

Diplomat Specialty Pharmacy Great Lakes Distribution Center, LLC

Diplomat Specialty Pharmacy of Southern California, LLC

Navigator Pharmacy Service, LLC

Burman’s Apothecary, L.L.C.

 

 

	
By:
    	
/s/ Gary W. Kadlec
    	
 
    
	
Name:
    	
Gary W. Kadlec
    	
 
    
	
Title:
    	
President
    	
 
    

 

Burman’s Apothecary, L.L.C. on behalf of the following entity of which Burman’s Apothecary, L.L.C. is the sole member:

 

Burman’s Media Pharmacy, LLC

 

	
By:
    	
/s/ Gary W. Kadlec
    	
 
    
	
Name:
    	
Gary W. Kadlec
    	
 
    
	
Title:
    	
President
    	
 
    

 

 

ACKNOWLEDGED AND AGREED BY: 

 

BioRx, LLC

 

	
By:
    	
/s/ Eric Hill
    	
 
    
	
Name:
    	
Eric Hill
    	
 
    
	
Title:
    	
Vice President
    	
 
    

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]